Johnson & Johnson surpassed Wall Street expectations for its second-quarter financial results, reporting $25.31 billion in total sales—a 6.6% increase year-over-year. Driven by strong demand for immunology drug Tremfya and oncology treatment Darzalex, the healthcare giant raised its full-year guidance, now projecting mid-point sales of $101.1 billion and adjusted earnings of $11.68 per share.
Pharmaceutical Performance Powers Growth
J&J’s pharmaceutical division remains the engine of the company’s financial success, generating $16.38 billion in quarterly revenue. This figure comfortably beat the $16.1 billion estimate from analysts tracked by LSEG data. The standout performer was Tremfya, which treats psoriasis and inflammatory bowel disease. Sales for the drug surged 72.5% to $2 billion, significantly outpacing the consensus estimate of $1.74 billion.
As Stelara faces revenue declines following the loss of its patent protection, Tremfya has emerged as a primary replacement asset. Meanwhile, the blood cancer treatment Darzalex continues to provide steady returns, posting $4.2 billion in sales for the quarter, aligning with market expectations.
Did you know?
J&J manages a portfolio of 28 platforms that each generate at least $1 billion in annual revenue, providing the company with significant financial insulation against the volatility of any single product.
Medical Technology and the Abiomed Challenge
While the pharmaceutical segment thrived, the medical technology unit reported $8.93 billion in sales, falling slightly short of analyst projections. A significant factor in this underperformance was the Abiomed franchise, which J&J acquired in 2022.
According to CFO Joseph Wolk, sales for the Abiomed heart pumps declined 2% year-over-year, a stark contrast to the 14% growth recorded in the first quarter. Wolk attributed this dip to a recent U.K. study that questioned the use of Impella pumps during specific high-risk coronary procedures. Despite the setback, the company maintains a positive outlook for the franchise. “We have a big data set coming out probably in the first half of next year that should allay any fears,” Wolk stated.
Strategic Outlook and Financial Guidance
Bolstered by its pharmaceutical momentum, J&J has adjusted its financial targets upward. The company raised its full-year adjusted earnings per share forecast from $11.55 to $11.68 at the midpoint.
Pro Tip: When evaluating pharmaceutical stocks, look beyond top-line revenue. Focus on “replacement assets”—drugs like Tremfya that are positioned to capture market share from legacy products losing patent exclusivity.
Frequently Asked Questions
- Why did J&J’s medical technology sales miss expectations?
The decline in Abiomed heart pump sales, influenced by a recent U.K. study regarding procedural safety, contributed to the unit trailing analyst estimates. - How is J&J replacing lost Stelara revenue?
The company is leveraging rapid growth from its immunology drug, Tremfya, which saw a 72.5% sales increase in the second quarter. - What is the company’s new full-year profit forecast?
J&J raised its adjusted earnings per share forecast to $11.68 at the midpoint.
Stay informed on the latest shifts in the healthcare sector. Subscribe to our newsletter for weekly financial analysis or explore our archives for more in-depth reports on pharmaceutical market trends.
Keep reading
